Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...

In many cases, it's not until memory problems start creeping up that most people learn they have Alzheimer's disease. By then, the disease may already be progressing, leaving limited options for ...

Alzheimer’s disease is a devastating condition that affects more than 7 million Americans, according to the Alzheimer’s Association. As the Baby Boomer generation ages, this number is estimated to ...

When you buy through links on our articles, Future and its syndication partners may earn a commission. Amyloid plaques (depicted in orange) are a central feature of Alzheimer's disease in the brain. A ...

The test may make it easier to identify whether people with memory and thinking problems have Alzheimer’s or not. By Pam Belluck A blood test that can help diagnose Alzheimer’s disease has received ...

Diagnosing Alzheimer’s disease has long relied on expensive and invasive procedures, often delaying care until symptoms are well advanced. With the recent US Food and Drug Administration (FDA) ...

The earlier Alzheimer’s disease can be diagnosed, the better the outcomes; however, it can be hard to diagnose the disease in its earliest stages. The United States Food and Drug Administration ...

This transcript has been edited for clarity. Hi. I’m Art Caplan. I'm at the Division of Medical Ethics at NYU Grossman School of Medicine in New York City. The FDA recently cleared, for the first time ...

The U.S. Food and Drug Administration (FDA) recently cleared a blood test that detects signs of Alzheimer's disease in the brain, according to multiple studies. This is the first-ever blood test ...

The U.S. FDA recently approved a new blood test to diagnose Alzheimer’s disease. The test, called Lumipulse, measures two proteins in plasma: pTau217 and ß-Amyloid 1-42. These proteins clump together ...

In patients showing cognitive decline, a new blood test for Alzheimer's is expected to make diagnosis more convenient, accessible and inexpensive than other existing tests. When you purchase through ...